Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **combination therapy** used for *rabies post-exposure prophylaxis*. It consists of two components: - **Rabies vaccine, purified vero cell** (PVRV): An inactivated rabies virus vaccine produced using Vero cells, highly purified to minimize impurities and residual host DNA. The vaccine stimulates the immune system to produce neutralizing antibodies against rabies virus, thereby providing active immunization[2][3][4][6][7]. - **Equine rabies immunoglobulin** (ERIG): Purified antibodies from horses immunized with rabies virus, providing immediate passive immunity by neutralizing rabies virus at the site of exposure[5]. ERIG is typically heat-treated to increase purity and safety[5]. The combination is indicated for *post-exposure prophylaxis*—PVRV to induce long-term immunity and ERIG for immediate protection before the vaccine-induced immune response becomes effective[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies vaccine, purified vero cell + equine rabies immunoglobulin.